Newsroom Archives - Page 16 of 23 - Spectral Medical Inc

Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022

TORONTO, Canada – March 4, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Reports Progress on Tigris Clinical Trial

Patient mortality data continues to exceed expectationsRecent FDA approved SOFA amendment contributing to increased patient enrollment TORONTO, Canada – February 11, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...

Spectral Medical Announces U.S. FDA Approval of DIMI Trial Protocol Amendment

Amendment expected to overcome key pandemic challenges and improve both site and patient enrollment TORONTO, Canada – January 31, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical...

Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021

TORONTO, Canada – December 3, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that Chris Seto, Chief Executive Officer of Spectral Medical, is scheduled to...

Spectral Medical Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments

TORONTO, Canada – November 30, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will host a conference call at 2:00 PM EST on Thursday, December 2, 2021, to...

Spectral Medical Announces U.S. FDA Approval of Tigris Trial Protocol Amendment to Expand Inclusion Criteria

Amendment aligns eligibility for Tigris with current clinical practice in septic shock Potential to improve Tigris enrollment rates by 25% to 50% and reduce time to trial completion Five additional clinical sites now participating with 15 total sites fully on board...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.